Retrospective analysis of anti-inflammatory therapies during the first wave of COVID-19 at a community hospital

Table 3 Univariate Cox proportional hazards survival analysis of pharmacological and therapeutic interventions in coronavirus disease 2019 intensive care unit patients

	B	SE	P value	HR	95%CI
GC (all patients)	-0.84	0.16	< 0.001	0.45	0.38-0.61
Vasopressors	0.039	35	0.027	1.4	1.05-2.1
IV ascorbic acid	0.1	0.15	0.49	1.1	0.91-1.5
Hydroxychloroquine	-0.58	0.36	0.1	0.56	0.27-1.14
Azithromycin	0.25	28	0.39	1.3	0.72-2.3
Heparin therapeutic dose	0.15	0.35	0.67	1.16	0.51-2.31
Heparin prophylaxis dose	-0.27	0.3	0.35	0.76	0.48-1.3
Convalescent plasma	0.29	1	0.77	1.3	0.72-9.8
Remdesivir	6 (3)	0
Prone positioning	0.36	0.52	0.44	1.43	0.51-1.4
Tocilizumab	-0.48	0.27	0.08	0.61	0.36-1.06
GC only	-0.75	0.21	0.001	0.47	0.18-0.41
GC + tocilizumab	-1.3	0.21	<0.001	0.27	0.4-1.15

HR: Hazard ratio; CI: Confidence interval; GC: Glucocorticoids; IV: Intravenous.